Kingswood Wealth Advisors LLC Invests $80,000 in Trevi Therapeutics, Inc. $TRVI

Kingswood Wealth Advisors LLC bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 14,632 shares of the company’s stock, valued at approximately $80,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Trevi Therapeutics by 9.4% in the first quarter. Vanguard Group Inc. now owns 3,838,032 shares of the company’s stock worth $24,141,000 after purchasing an additional 328,819 shares during the last quarter. MPM Bioimpact LLC grew its holdings in shares of Trevi Therapeutics by 10.8% in the first quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company’s stock worth $21,564,000 after purchasing an additional 333,470 shares during the last quarter. Octagon Capital Advisors LP bought a new stake in Trevi Therapeutics in the first quarter valued at $20,895,000. Armistice Capital LLC bought a new stake in Trevi Therapeutics in the first quarter valued at $18,795,000. Finally, Acorn Capital Advisors LLC boosted its holdings in Trevi Therapeutics by 7.2% in the first quarter. Acorn Capital Advisors LLC now owns 2,144,844 shares of the company’s stock valued at $13,491,000 after acquiring an additional 143,796 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Trading Up 0.7%

Shares of Trevi Therapeutics stock opened at $9.99 on Monday. The firm has a market capitalization of $1.22 billion, a P/E ratio of -23.79 and a beta of 0.74. The business has a fifty day simple moving average of $8.15 and a two-hundred day simple moving average of $6.98. Trevi Therapeutics, Inc. has a 12 month low of $2.36 and a 12 month high of $10.16.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on TRVI. Cantor Fitzgerald began coverage on shares of Trevi Therapeutics in a report on Tuesday, July 1st. They issued an “overweight” rating and a $25.00 price target on the stock. Raymond James Financial cut their price target on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. Morgan Stanley began coverage on shares of Trevi Therapeutics in a report on Thursday, August 21st. They issued an “overweight” rating and a $18.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, October 8th. Finally, Needham & Company LLC cut their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.75.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.